Bioweapons of tumor mass destruction?

More than an attachment module: covalent inhibitor warheads influence BTK dynamics and function.

bioRxiv : the preprint server for biology·2026

Chronic lymphocytic leukemia with IGH::BCL3-translocation is characterized by a homogeneous and distinct genetic and epigenetic landscape.

HemaSphere·2026

The spectrum of immunoglobulin heavy chain enhancer hijacking in chronic lymphocytic leukemia.

Leukemia·2026

What does BCL-2 do? From new molecular insights to the clinical implications.

Cell death and differentiation·2026

The BH3-only protein NOXA is essential for apoptosis induction by BH3-mimetics targeting BCL2 or BCL-XL in DLBCL.

British journal of haematology·2025

The unfolded protein response influences therapy outcome and disease progression in chronic lymphocytic leukaemia.

Scientific reports·2025

Perioperative Durvalumab for Resectable Non-Small Cell Lung Cancer: Updated Outcomes From the Phase III AEGEAN Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Long-Term Survival Outcomes of Modified-FOLFOXIRI Plus Cetuximab Versus Bevacizumab in RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Analysis of the DEEPER Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Refined Continuous Risk Index for Accurately Predicting Outcomes of Patients With Chronic Lymphocytic Leukemia After Limited-Duration Therapy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Medical Therapy for Hormone Receptor-Positive, HER2-Negative Stage I-III Breast Cancer: ASCO Living Guideline, Version 2026.1.0.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Salvage Hypofractionated Accelerated Versus Standard Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: A Phase III Randomized Clinical Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

The Patient Who Could Not Die.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Silencing GJB2 attenuates IL-1β-induced chondrocyte injury by activating Nrf2/HO-1 signaling and preserving mitochondrial function.

Folia histochemica et cytobiologica·2026

DPM2 promotes melanoma progression and serves as a prognostic factor.

Melanoma research·2026

Efficacy of combined atorvastatin and paromomycin in treating experimental cryptosporidiosis in immunosuppressed mice.

QJM : monthly journal of the Association of Physicians·2026

Pan-RAS Inhibitor Shows Activity in Advanced Lung Cancer.

Cancer discovery·2026

Purine nucleoside phosphorylase in breast cancer from metabolic regulation to targeted therapy: challenges and opportunities.

RSC medicinal chemistry·2026

Yifeixiaoji decoction as an adjunct to osimertinib therapy in advanced EGFR-mutated NSCLC: protocol for a randomized, double-blind, placebo-controlled trial.

Frontiers in medicine·2026

Related Experiment Videos

Bioweapons of tumor mass destruction?

Related Concept Videos

More than an attachment module: covalent inhibitor warheads influence BTK dynamics and function.

Chronic lymphocytic leukemia with IGH::BCL3-translocation is characterized by a homogeneous and distinct genetic and epigenetic landscape.

The spectrum of immunoglobulin heavy chain enhancer hijacking in chronic lymphocytic leukemia.

What does BCL-2 do? From new molecular insights to the clinical implications.

The BH3-only protein NOXA is essential for apoptosis induction by BH3-mimetics targeting BCL2 or BCL-XL in DLBCL.

The unfolded protein response influences therapy outcome and disease progression in chronic lymphocytic leukaemia.

Perioperative Durvalumab for Resectable Non-Small Cell Lung Cancer: Updated Outcomes From the Phase III AEGEAN Trial.

Long-Term Survival Outcomes of Modified-FOLFOXIRI Plus Cetuximab Versus Bevacizumab in RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Analysis of the DEEPER Trial.

Refined Continuous Risk Index for Accurately Predicting Outcomes of Patients With Chronic Lymphocytic Leukemia After Limited-Duration Therapy.

Medical Therapy for Hormone Receptor-Positive, HER2-Negative Stage I-III Breast Cancer: ASCO Living Guideline, Version 2026.1.0.

Salvage Hypofractionated Accelerated Versus Standard Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: A Phase III Randomized Clinical Trial.

The Patient Who Could Not Die.

Silencing GJB2 attenuates IL-1β-induced chondrocyte injury by activating Nrf2/HO-1 signaling and preserving mitochondrial function.

DPM2 promotes melanoma progression and serves as a prognostic factor.

Efficacy of combined atorvastatin and paromomycin in treating experimental cryptosporidiosis in immunosuppressed mice.

Pan-RAS Inhibitor Shows Activity in Advanced Lung Cancer.

Purine nucleoside phosphorylase in breast cancer from metabolic regulation to targeted therapy: challenges and opportunities.

Yifeixiaoji decoction as an adjunct to osimertinib therapy in advanced EGFR-mutated NSCLC: protocol for a randomized, double-blind, placebo-controlled trial.

Related Experiment Videos

Bioweapons of tumor mass destruction?

Related Concept Videos

Related Articles